Huynh, Hung <br/><br/>
Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.  [electronic resource] 

 -  Molecular cancer therapeutics  Jan 2007 
 - 138-46 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1535-7163 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-06-0436  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Benzimidazoles--pharmacology<br/>Carcinoma, Hepatocellular--drug therapy<br/>Caspase 3--metabolism<br/>Caspase 7--metabolism<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Extracellular Signal-Regulated MAP Kinases--antagonists & inhibitors<br/>Humans<br/>Liver Neoplasms--drug therapy<br/>MAP Kinase Kinase Kinase 1--antagonists & inhibitors<br/>Mice<br/>Mice, SCID<br/>Phosphorylation--drug effects<br/>Poly(ADP-ribose) Polymerases--metabolism<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins B-raf--metabolism<br/>Ribosomal Protein S6 Kinases, 90-kDa--antagonists & inhibitors<br/>Time Factors<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays